Market revenue in 2024 | USD 46.9 million |
Market revenue in 2030 | USD 32.2 million |
Growth rate | -6.6% (CAGR from 2025 to 2030) |
Largest segment | Eylea |
Fastest growing segment | Vabysmo |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Eylea, Lucentis, Beovu, Vabysmo |
Key market players worldwide | Roche Holding AG ADR, Biogen Inc, Pfizer Inc, Amgen Inc, Bausch Health Companies Inc, Viatris Inc, Coherus BioSciences Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-vascular endothelial growth factor therapeutics market will help companies and investors design strategic landscapes.
Eylea was the largest segment with a revenue share of 56.5% in 2024. Horizon Databook has segmented the South Korea anti-vascular endothelial growth factor therapeutics market based on eylea, lucentis, beovu, vabysmo covering the revenue growth of each sub-segment from 2018 to 2030.
South Korea’s anti-VEGF market is characterized by a stable emphasis on healthcare innovation, backed by substantial government funding for research and development in biopharmaceuticals. With a quickly aging population and a high incidence of diabetes-related eye conditions, demand for effective anti-VEGF therapies such as Lucentis and Eylea are surging.
Local companies are increasingly active in biosimilar development, supported by favorable regulatory pathways and government incentives. This domestic push not only strengthens South Korea’s position in the Asia-Pacific therapeutics market but also promises to bring down treatment costs, thereby widening access among an increasingly healthconscious population.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea anti-vascular endothelial growth factor therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into South Korea anti-vascular endothelial growth factor therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account